DOSAGE AND ADMINISTRATION
Ranexa dosing should be initiated at 500 mg b.i.d. and increased to 1000 mg b.i.d., as needed, based on clinical symptoms. The maximum recommended daily dose of Ranexa is 1000 mg b.i.d. Baseline and follow-up ECGs should be obtained to evaluate effects on QT interval. Use of QT prolonging drugs and drugs that increase plasma concentrations of ranolazine should be avoided (see CONTRAINDICATIONS, WARNINGS and PRECAUTIONS, Drug-Drug Interactions).
The dose of simvastatin and digoxin and other P-gp substrates may have to be reduced when ranolazine is co-administered. Dose adjustments of Ranexa are generally not required on the basis of age or gender, or in patients with CHF or diabetes mellitus.
The concomitant use of Ranexa with other commonly administered cardiovascular medications (amlodipine, beta-blockers, nitrates, anti-hypertensive agents) is well-tolerated.
If a dose of Ranexa is missed, the prescribed dose should be taken at the next scheduled time. The next dose should not be doubled.
Ranexa may be taken with or without meals. Ranexa tablets should be swallowed whole and not crushed, broken, or chewed.